Guillain-Barr Syndrome Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.IVIG Versus Plasmapheresis in the Treatment of Guillian Barrie Syndrome Patients
Condition: Guillain-Barre Syndrome Interventions: Device: plasmapheresis device; Drug: Intravenous immunoglobulin Sponsor: Assiut University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 3, 2021 Category: Research Source Type: clinical trials
Johnson & Johnson Statement on COVID-19 Vaccine Following Reports of Guillain-Barre ́ Syndrome
NEW BRUNSWICK, N.J., July 12, 2021 -- The safety and well-being of the people who use our products is our number one priority.
Rare cases of the neurological disorder, Guillain-Barre ́ syndrome have been reported following vaccination with the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 12, 2021 Category: Pharmaceuticals Source Type: clinical trials
Predictors and Prognostic Factors of Gullian Barrie Syndrome Outcome
Condition: Guillain-Barre Syndrome Intervention: Device: plasmapheresis Sponsor: Assiut University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 16, 2021 Category: Research Source Type: clinical trials
